DE69823931D1 - Chromatographieverfahren für Reinigung von IgG mit hoher Ausbeute und Virusinaktivierung - Google Patents

Chromatographieverfahren für Reinigung von IgG mit hoher Ausbeute und Virusinaktivierung

Info

Publication number
DE69823931D1
DE69823931D1 DE69823931T DE69823931T DE69823931D1 DE 69823931 D1 DE69823931 D1 DE 69823931D1 DE 69823931 T DE69823931 T DE 69823931T DE 69823931 T DE69823931 T DE 69823931T DE 69823931 D1 DE69823931 D1 DE 69823931D1
Authority
DE
Germany
Prior art keywords
antibodies
caprylate
purification
solution
precipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823931T
Other languages
English (en)
Other versions
DE69823931T2 (de
Inventor
Wytold R Lebing
Patricia Alred
Doug C Lee
Hanns-Ingolf Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25374006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69823931(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of DE69823931D1 publication Critical patent/DE69823931D1/de
Application granted granted Critical
Publication of DE69823931T2 publication Critical patent/DE69823931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/22—Blood or products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69823931T 1997-06-20 1998-06-09 Chromatographieverfahren für Reinigung von IgG mit hoher Ausbeute und Virusinaktivierung Expired - Lifetime DE69823931T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/879,362 US5886154A (en) 1997-06-20 1997-06-20 Chromatographic method for high yield purification and viral inactivation of antibodies
US879362 1997-06-20

Publications (2)

Publication Number Publication Date
DE69823931D1 true DE69823931D1 (de) 2004-06-24
DE69823931T2 DE69823931T2 (de) 2005-06-16

Family

ID=25374006

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823931T Expired - Lifetime DE69823931T2 (de) 1997-06-20 1998-06-09 Chromatographieverfahren für Reinigung von IgG mit hoher Ausbeute und Virusinaktivierung

Country Status (10)

Country Link
US (5) US5886154A (de)
EP (1) EP0893450B1 (de)
JP (1) JP4359347B2 (de)
AT (1) ATE267214T1 (de)
AU (1) AU749336B2 (de)
CA (2) CA2239237C (de)
DE (1) DE69823931T2 (de)
DK (1) DK0893450T3 (de)
ES (1) ES2221096T3 (de)
PT (1) PT893450E (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403989B (de) 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
JP4685238B2 (ja) * 1998-06-09 2011-05-18 ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
JP3096737B1 (ja) * 1999-07-19 2000-10-10 工業技術院長 ヒト・動物細胞培養液
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
WO2002072615A1 (fr) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
US20040116676A1 (en) * 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
BRPI0507298A (pt) * 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
CN1922207B (zh) * 2004-02-27 2012-06-06 奥克特珐玛股份有限公司 提供纯化的、病毒安全的抗体制剂的方法
JP2008500972A (ja) * 2004-05-14 2008-01-17 キリンファーマ株式会社 免疫グロブリンの精製方法
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
CN100339386C (zh) * 2005-09-12 2007-09-26 大连三仪动物药品有限公司 动物用复合型免疫球蛋白的生产方法
US20070128693A1 (en) * 2005-12-06 2007-06-07 Advantek Serum Laboratories Limited3/F Method for the inactivation and removal of dengue virus from biological samples
JP5697847B2 (ja) * 2006-01-30 2015-04-08 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＩｇＭを使用する治療方法および予防方法
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
EP2069387A4 (de) * 2006-06-14 2011-02-02 Glaxosmithkline Llc Verfahren zur reinigung von antikörpern mithilfe von keramik-hydroxyapatit
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
AU2013204044B2 (en) * 2007-11-30 2017-08-31 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
EP2271382B1 (de) 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Zweistufige Ultrafiltrierung/Diafiltrierung
US20110065900A1 (en) * 2008-05-30 2011-03-17 Ge Healthcare Bio-Science Ab Separation method utilizing polyallylamine ligands
EP2435474A2 (de) 2009-05-27 2012-04-04 Baxter International Inc Verfahren zur herstellung einer hochkonzentrierten immunglobulinzuberei­tung für die subkutane anwendung
EP2445925A1 (de) * 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2011244947B2 (en) * 2010-05-26 2012-06-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
KR20130128382A (ko) * 2010-10-13 2013-11-26 옥타파마 아게 보체 인자 ｈ의 정제 방법
EP2649016B1 (de) * 2010-12-06 2020-06-10 Pall Corporation Verfahren zur kontinuierlichen verarbeitung biologischer produkte
DE102010054767B4 (de) 2010-12-16 2013-02-21 Previpharma Ag Verfahren zur Trennung, Aufkonzentration und/oder Reinigung von (Blut)Plasmaprotein, Viren oder Virenbestandteilen
DE102010054766B4 (de) 2010-12-16 2012-08-30 Previpharma Ag Verfahren zur Trennung, Aufkonzentration oder Reinigung eines (Blut)Plasmaproteins oder Virenbestandteils aus einer Mischung
ES2675353T3 (es) 2011-02-04 2018-07-10 Octapharma Ag Procedimiento para inactivación/eliminación de factores de coagulación por precipitación
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
CN102250240B (zh) * 2011-06-27 2013-07-31 山东泰邦生物制品有限公司 一种从血浆分离组分ⅰ+ⅲ中纯化人免疫球蛋白的方法
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
KR102170615B1 (ko) 2012-02-29 2020-10-28 박스알타 인코퍼레이티드 말초 신경의 IgG 자극된 재수초화
CA2866634C (en) 2012-03-09 2022-07-19 Csl Behring Ag Compositions comprising secretory-like immunoglobulins
EP2636681A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Verfahren zur Anreicherung von IgA
EP2636684A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Vorbeugung von Infektionen
ES2381828B1 (es) 2012-03-20 2012-11-16 Grifols, S.A. PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
ES2895173T3 (es) * 2012-06-29 2022-02-17 Emd Millipore Corp Métodos para inactivar virus durante un proceso de purificación de proteínas
AU2013205138B2 (en) * 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
RS60226B1 (sr) 2012-09-07 2020-06-30 Coherus Biosciences Inc Stabilne vodene formulacije adalimumaba
KR20150118103A (ko) * 2013-02-06 2015-10-21 에이전시 포 사이언스, 테크놀로지 앤드 리서치 단백질 정제 방법
SG10201709131UA (en) 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
JP6474798B2 (ja) * 2013-07-01 2019-02-27 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 方法
SG10201811186XA (en) 2013-10-18 2019-01-30 Novasep Process Purification of proteins
ES2817928T3 (es) 2013-11-15 2021-04-08 Novartis Ag Eliminación de impurezas de cultivos celulares residuales
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
KR101917197B1 (ko) * 2014-03-11 2018-11-09 주식회사 녹십자홀딩스 면역글로불린의 정제방법
DK3131589T3 (da) * 2014-04-15 2023-08-07 Boehringer Ingelheim Int Fremgangsmåde og anvendelse til fortløbende inaktivering af en virus under tilvejebringelse af et biologisk produkt
ES2857582T3 (es) * 2014-04-30 2021-09-29 Novo Nordisk As Métodos para la purificación de proteínas mediante el uso de ácido caprílico
WO2015195452A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
ES2742704T3 (es) 2014-06-25 2020-02-17 Emd Millipore Corp Elementos, módulos y sistemas de filtro compactos, enrollados en espiral
EP3010626B1 (de) 2014-08-29 2022-12-14 EMD Millipore Corporation Verfahren zum filtrieren von flüssigkeiten mit querstromfilterungssystemen mit einzelnen durchgängen sowie querstromfilterungssysteme mit retentatrückführung
WO2016033546A1 (en) 2014-08-29 2016-03-03 Emd Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
CA2954425C (en) 2014-09-02 2019-05-07 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
US9556253B2 (en) 2014-12-02 2017-01-31 Hemarus Therapeutics Limited Process for increased yield of immunoglobulin from human plasma
EP3230299A1 (de) 2014-12-08 2017-10-18 EMD Millipore Corporation Mischbettionenaustauschadsorber
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
TR201905974T4 (tr) 2015-08-31 2019-05-21 Inst Grifols S A İmmünoglobuli̇nleri̇n hazirlanmasi i̇çi̇n yöntem
CN105126100B (zh) * 2015-09-23 2021-01-26 成都蓉生药业有限责任公司 一种富含IgM的人免疫球蛋白制剂及其制备方法
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
JP6370853B2 (ja) * 2016-09-26 2018-08-08 インスティトゥト グリフォルス，ソシエダ アノニマ 免疫グロブリンの調製方法
EP3528787A4 (de) 2016-10-21 2020-05-06 Amgen Inc. Pharmazeutische formulierungen und verfahren zur herstellung davon
BE1025090B1 (fr) * 2017-03-30 2018-10-29 Univercells Sa Procede et kit de purification de proteines
US11312746B2 (en) 2018-05-17 2022-04-26 Csl Behring Ag Method and system of protein extraction
BR112021003420A2 (pt) 2018-08-31 2021-05-18 Genzyme Corporation resina cromatográfica estéril e uso da mesma em processos de manufatura
CA3157446A1 (en) 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
JP2023519956A (ja) 2020-03-31 2023-05-15 武田薬品工業株式会社 Ｃ－１インヒビター欠乏血漿から免疫グロブリン製剤を生産する方法
WO2021239790A1 (en) 2020-05-27 2021-12-02 Grifols Worldwide Operations Limited Method for the treatment of virus infection with ivig and convalescent plasma
EP4161572A1 (de) 2020-06-03 2023-04-12 Grifols Worldwide Operations Limited Hyperimmune igg- und/oder igm-zusammensetzungen und verfahren zu ihrer herstellung und verfahren zur gewinnung von hyperimmunem menschlichem plasma aus einem spender
UY39318A (es) 2020-07-10 2022-02-25 Grifols Worldwide Operations Ltd Procedimiento para obtener una composicion que comprende inmunoglobulina m derivada de plasma humano
CN111991571B (zh) * 2020-08-12 2022-04-05 湖州师范学院 一种柱上低pH病毒灭活的方法
CN112500477B (zh) * 2020-12-05 2023-06-06 贵州泰邦生物制品有限公司 一种快速从血浆提取人免疫球蛋白的方法
CA3220221A1 (en) * 2021-05-26 2022-12-01 Ibrahim EL MENYAWI Plasma fractionation by continuous extraction
EP4377361A1 (de) 2021-07-29 2024-06-05 CSL Behring AG Verfahren zur reinigung von immunglobulin g und verwendungen davon
WO2023194944A1 (en) 2022-04-08 2023-10-12 Csl Behring Ag Methods of sanitizing and/or regenerating a chromatography medium
BE1029863B1 (nl) * 2022-05-10 2023-05-12 Prothya Biosolutions Belgium WERKWIJZEN VOOR HET PRODUCEREN VAN IMMUNOGLOBULINE G (IgG) PREPARATEN EN/OF OPLOSSINGEN
WO2024003171A1 (en) 2022-06-28 2024-01-04 Csl Behring Ag Method of monitoring parameters in turbid solutions
WO2024105235A1 (en) 2022-11-18 2024-05-23 Grifols Worldwide Operations Limited Hyperimmune globulin compositions for use in the treatment of covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190437B1 (de) 1972-07-05 1975-08-08 Merieux Inst
US4156681A (en) 1974-03-28 1979-05-29 Plasmesco Ag Process for isolating albumin from blood
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
CA1201063A (en) * 1982-07-20 1986-02-25 Winnipeg Rh Institute Inc., (The) Process for preparing purified immune globulin (igg)
US4434093A (en) 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
US4639513A (en) * 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4983722A (en) * 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
DE3821295A1 (de) * 1988-06-24 1989-12-28 Kernforschungsz Karlsruhe Verfahren zur abtrennung von technetium, ruthenium und palladium aus kernbrennstoff-loesungen
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927112C1 (de) 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
JPH0778025B2 (ja) 1990-03-20 1995-08-23 日本赤十字社 免疫グロブリンｇの製造方法
DE59009020D1 (de) * 1990-03-22 1995-06-08 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates.
US5110910A (en) * 1991-03-25 1992-05-05 Miles Inc. Virucidal euglobulin precipitation
US5164587A (en) 1991-09-09 1992-11-17 Harbor Branch Oceanographic Institution, Inc. Polarimetric parameter measurement systems and methods for measuring a plurality of parameters
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
JPH1129494A (ja) 1999-02-02
CA2239237A1 (en) 1998-12-20
DK0893450T3 (da) 2004-09-13
CA2676074A1 (en) 1998-12-20
USRE43655E1 (en) 2012-09-11
CA2676074C (en) 2015-10-06
ATE267214T1 (de) 2004-06-15
ES2221096T3 (es) 2004-12-16
US20020177693A1 (en) 2002-11-28
USRE44558E1 (en) 2013-10-22
EP0893450A1 (de) 1999-01-27
AU7009998A (en) 1998-12-24
PT893450E (pt) 2004-09-30
US6307028B1 (en) 2001-10-23
AU749336B2 (en) 2002-06-27
CA2239237C (en) 2010-02-02
DE69823931T2 (de) 2005-06-16
US5886154A (en) 1999-03-23
JP4359347B2 (ja) 2009-11-04
EP0893450B1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
ATE267214T1 (de) Chromatographieverfahren für reinigung von igg mit hoher ausbeute und virusinaktivierung
DK450785D0 (da) Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed
DE3778086D1 (de) Herstellungsverfahren von quaternaeren ammoniumhydroxiden von hoher reinheit.
ES2139227T3 (es) Concentrado de fibrinogeno obtenido de plasma sanguineo, procedimiento e instalacion para su preparacion.
NZ226651A (en) Ion exchange protein separation method characterised by adjusting ph so that the pure protein and the impurity are oppositely charged
EP0309787A3 (en) Process for producing a highly purified, virus-free and biologically active transferrin preparation
AU2253392A (en) Therapeutic fragments of von willebrand factor
DE69631229D1 (de) Herstellung von virusinaktivierten Intravenös injektierbaren Globulin aus Immunserum
DE3062792D1 (en) A process in purification and concentration of the factor viii-complex
Trupin et al. Variation in prolyl hydroxylase activity of keloid-derived and normal human fibroblasts in response to hydrocortisone and ascorbic acid
DE69303941D1 (de) Verfahren zur Herstellung von hochreinem Fibrinogen
EP0892045A3 (de) Verfahren zur Herstellung eines eine Hyaluronidase enthaltenden Präparats
JPS62111953A (ja) グリシンとｌ−セリンの分離方法
SE435787B (sv) Forfarande for framstellning av immunoglobulinderivat
DE3170868D1 (en) Process for the preparation of highly purified antihemophilic factor
DE3823519A1 (de) Verfahren zur reinigung von aktiviertem protein c
JPS61234792A (ja) マウスインタ−フエロンの精製法
KR930006151A (ko) 지렁이로부터 프로테아제를 분리 정제하는 방법
FR2623506B1 (fr) Procede de preparation de synthons peptidiques
JPS61181395A (ja) マウスインタ−フエロンの精製法
KR910016926A (ko) 인간 β-인터페론의 정제방법
RO85360B1 (ro) Procedeu de obtinere a fosfatazei alcaline

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings